Foamix up 4% on new U.S. patent covering acne treatment

Foamix Pharmaceuticals (FOMX +4.1%) is up, albeit on below-average volume, in response to its receipt of a new U.S. patent covering the topical use of certain minocycline formulations for the once-daily treatment for at least seven consecutive days of acne vulgaris within middle adolescence.

The patent, No. 10,398,641, wll be in effect until September 2037.

https://seekingalpha.com/news/3497011-foamix-4-percent-new-u-s-patent-covering-acne-treatment